Litigation Details for CELGENE CORPORATION v. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED (D.N.J. 2018)

CELGENE CORPORATION v. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED (D.N.J. 2018)

Docket		Date Filed	2018-08-31
Court	District Court, D. New Jersey	Date Terminated	2019-09-18
Cause	15:1126 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	6,315,720; 6,561,977; 6,755,784; 6,869,399; 7,141,018; 7,230,012; 7,959,566; 8,315,886; 8,626,531
Link to Docket	External link to docket

Details for CELGENE CORPORATION v. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-08-31	1	Complaint	prior to the expiration of United States Patent Nos. 6,315,720 (the “’720 …140 PageID: 2 patent”), 6,561,977 (the “’977 patent”), 6,755,784 (the “’784 patent”), 6,869,399 (the…the “’399 patent”), 7,141,018 (the “’018 patent”), 7,230,012 (the “’012 patent”), 7,959,566 (the “’566…566 patent”), 8,315,886 (the “’886 patent”), and 8,626,531 (the “’531 patent”), all owned by Celgene … 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C	External link to document

Celgene Corporation v. Hikma Pharmaceuticals: Litigation Summary, Patent Risk, and Generic Lenalidomide Entry

Last updated: August 27, 2026

Celgene Corporation sued Hikma Pharmaceuticals International Ltd. in the U.S. District Court for the District of New Jersey after Hikma filed an abbreviated new drug application (ANDA) seeking approval to market generic lenalidomide capsules, the active ingredient in Revlimid. The case, No. 2:18-cv-13477-SDW-LDW, was part of Celgene’s broader patent campaign against generic manufacturers.

The dispute ended without a merits judgment. The public docket reflects a negotiated resolution and dismissal rather than a trial ruling on patent validity, infringement, or enforceability. Hikma later entered the U.S. generic lenalidomide market under the commercial framework governing generic Revlimid launches. The case therefore has greater significance as an entry-timing and settlement matter than as a precedential patent decision.

What was Celgene v. Hikma about?

Celgene’s complaint followed Hikma’s Paragraph IV certification against patents listed for Revlimid in the FDA’s Orange Book. Hikma’s proposed product was generic lenalidomide capsules for indications covered by Revlimid’s labeling.

Celgene alleged that Hikma’s ANDA product would infringe patents covering:

• Lenalidomide compositions and pharmaceutical formulations.
• Methods of treating multiple myeloma and other hematologic disorders.
• Dosing regimens and treatment protocols.
• The controlled-distribution and risk-management infrastructure associated with Revlimid.

Hikma’s ANDA filing created a statutory basis for patent litigation under the Hatch-Waxman Act. Celgene’s complaint triggered the statutory 30-month stay of FDA approval, subject to earlier termination or modification under the statute. The case was assigned to Judge Susan D. Wigenton, with Magistrate Judge Lois H. Wilkinson handling pretrial matters. [1]

Case identification

Item	Detail
Plaintiff	Celgene Corporation
Defendants	Hikma Pharmaceuticals International Ltd. and related Hikma entities
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:18-cv-13477-SDW-LDW
Product	Generic lenalidomide capsules
Reference drug	Revlimid
Active ingredient	Lenalidomide
Statutory framework	Hatch-Waxman Act, including Paragraph IV
Judicial outcome	Settlement-related dismissal; no reported merits judgment

Which Revlimid patents were relevant to generic lenalidomide?

Revlimid was protected by a layered patent estate rather than a single blocking patent. The estate included composition, polymorph, formulation, method-of-use, dosing, and risk-management-related rights. The applicable Orange Book listings changed over time as patents expired, were delisted, or reached the end of their enforceable terms.

Celgene’s commercial strategy relied on combining several categories of patents:

1. Core compound and chemical patents.
2. Solid-state and formulation patents.
3. Method-of-treatment patents.
4. Dose and schedule patents.
5. Patents associated with restricted distribution and patient-monitoring procedures.

The earliest compound protection did not determine the practical date of generic entry. Later-expiring method and formulation patents were more important to settlement negotiations because a generic applicant could challenge those patents even after earlier composition patents expired.

How did the patent estate affect generic entry?

The patent estate created several potential entry scenarios:

Entry route	Commercial effect
Full Paragraph IV success	Potential launch before the latest listed patent expiration
Settlement with an agreed launch date	Controlled entry without a merits decision
Section viii carve-out	Approval for indications or uses outside the patented labeling
Authorized generic or license	Entry under Celgene or Bristol Myers Squibb commercial terms
Post-expiration entry	Broad approval after remaining blocking claims expire

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents and exclusivity information submitted for approved products. Patent scope must be assessed against the ANDA formulation, proposed labeling, manufacturing process, and certification language. [2]

When did Revlimid lose exclusivity?

Revlimid lost portions of its exclusivity at different times. The principal compound protection expired before the later method-of-use and formulation protections. Celgene’s settlement strategy sought to preserve commercial control after core compound protection weakened.

Regulatory and patent timeline

Date or period	Event
2005	FDA approval of Revlimid for specified hematologic indications
2010s	Celgene obtained and enforced additional method, formulation, and use-related patents
2018	Hikma filed an ANDA with Paragraph IV certifications; Celgene filed suit
2019-2021	Celgene pursued settlements with multiple generic applicants
2022	FDA-approved generic lenalidomide products began entering the U.S. market under settlement and launch arrangements
2027	Frequently cited outer boundary for certain later Revlimid patent protections, subject to patent-specific expiration, terminal disclaimers, pediatric extensions, and settlement terms

The 2027 date should not be treated as a single patent expiration date for every strength, indication, or use. Different patents can expire on different dates, and a generic may enter before the final nominal expiration under a license or settlement.

Did Hikma file a Paragraph IV challenge?

Yes. The complaint was based on Hikma’s ANDA and its certifications challenging Revlimid-related Orange Book patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product.

The certification exposed Hikma to patent litigation but also allowed Hikma to seek an approval path before the listed patents’ expiration. Celgene responded with an infringement complaint, which is the standard Hatch-Waxman mechanism for converting an ANDA patent challenge into federal litigation.

The public disposition does not establish that Hikma prevailed on any patent claim. It also does not establish that Celgene’s patents were upheld. The case ended without a reported decision resolving infringement, validity, written description, enablement, obviousness, inequitable conduct, or claim construction.

What was the litigation status and outcome?

The litigation was resolved through a negotiated disposition rather than a trial. The docket does not reflect a final merits opinion adjudicating the asserted Revlimid patents against Hikma’s ANDA product.

Procedural assessment

Issue	Status
Complaint	Filed in the District of New Jersey
ANDA-related claims	Asserted under Hatch-Waxman procedures
Trial	No public merits trial outcome
Claim construction	No reported final Markman ruling resolving the commercial dispute
Patent validity	Not finally adjudicated in the public disposition
Patent infringement	Not finally adjudicated in the public disposition
Settlement	Reflected in the termination of the action
Final commercial result	Hikma obtained a path to U.S. generic lenalidomide commercialization

A dismissal following settlement generally prevents the case from producing a binding judicial conclusion on patent strength. For business analysis, the settlement date and launch rights are more material than the absence of a trial victory.

What did the Celgene-Hikma settlement mean for generic launch timing?

The settlement converted an uncertain litigation outcome into a negotiated launch framework. In the Revlimid market, settlements typically address:

• The earliest permitted generic launch date.
• The dosage strengths covered by the agreement.
• Product supply restrictions.
• Authorized-generic or licensed-product arrangements.
• Distribution controls imposed by the Revlimid risk-management program.
• Treatment of later-issued patents.
• Allocation of litigation costs and release of claims.

Hikma announced U.S. commercialization of generic lenalidomide capsules after FDA approval. Market entry occurred in a controlled environment because lenalidomide distribution is subject to strict handling and patient-safety requirements. The commercial launch did not represent unrestricted competition comparable to a conventional small-molecule generic with no distribution controls. [3]

Generic launch scenarios

The principal scenarios were:

1. A limited, settlement-authorized launch before expiration of all Revlimid patents.
2. A strength-by-strength launch based on FDA approval and supply availability.
3. A restricted-distribution launch reflecting the product’s safety controls.
4. Broader market competition after the remaining blocking patents expired.

The settlement reduced the probability of an immediate at-risk launch. An at-risk launch would have exposed Hikma to substantial damages if Celgene later prevailed on infringement and the asserted patents were upheld.

What FDA regulatory issues affected Hikma’s product?

Lenalidomide is a small-molecule drug, so Hikma pursued the ANDA pathway rather than the biosimilar pathway. Biosimilar risk is therefore not applicable to this case.

The regulatory barriers included:

• Demonstrating pharmaceutical equivalence to Revlimid.
• Demonstrating bioequivalence.
• Obtaining approval for the relevant capsule strengths.
• Matching or appropriately carving out patented indications.
• Complying with lenalidomide’s restricted distribution and pregnancy-prevention requirements.
• Establishing a distribution system capable of handling controlled dispensing and patient monitoring.

Revlimid’s safety program was historically administered through the Revlimid REMS. FDA later modified the program and distribution requirements, but lenalidomide remained subject to significant risk-management obligations because of teratogenicity and hematologic toxicity. [4]

These requirements created an operational barrier independent of patent protection. A manufacturer could obtain ANDA approval yet face implementation costs involving pharmacies, wholesalers, prescribers, patients, enrollment systems, and product tracking.

What formulation and method-of-use patents protected Revlimid?

Revlimid patent risk extended beyond the active pharmaceutical ingredient.

Formulation and composition claims

Formulation-related rights can cover:

• Capsule compositions.
• Solid forms or polymorphs of lenalidomide.
• Excipients and dosage-unit arrangements.
• Stability characteristics.
• Manufacturing or purification processes.

Such claims can create infringement risk even when the basic chemical compound is no longer protected.

Method-of-use claims

Method patents can cover:

• Treatment of multiple myeloma.
• Treatment of myelodysplastic syndromes.
• Combination treatment with dexamethasone or other agents.
• Specific dose levels.
• Treatment schedules.
• Patient-selection criteria.
• Maintenance or relapse settings.

A generic applicant may attempt a section viii labeling carve-out for patented uses. That strategy can reduce infringement risk but may also narrow the approved label and limit commercial uptake.

How strong was Celgene’s patent estate?

Celgene’s estate was commercially strong but legally fragmented. Its strength came from the number of patent categories and the high value of the Revlimid franchise, not from a single universally dominant patent.

Strength factors

• Multiple patent families covered different technical and clinical features.
• Revlimid had substantial revenue and a large installed patient base.
• Celgene had extensive Hatch-Waxman litigation experience.
• The product’s restricted distribution system raised technical and operational entry barriers.
• Method-of-use patents could preserve protection after compound patents expired.

Weakness factors

• Early compound protection had already eroded.
• Generic applicants could challenge each listed patent independently.
• Method patents can be vulnerable to divided-infringement and labeling arguments.
• Carve-outs can reduce exposure to some patented indications.
• Settlement pressure increases as multiple generic applicants approach launch.
• Orange Book listing does not establish patent validity or enforceability.

The absence of a merits ruling in the Hikma case means the litigation record does not provide a judicial scorecard for the asserted patent claims.

Which companies challenged Revlimid patents?

Celgene litigated against multiple generic applicants seeking lenalidomide approval. Publicly reported challengers included major generic manufacturers and suppliers such as Natco, Teva, Dr. Reddy’s Laboratories, and other ANDA applicants. Some disputes ended in settlements that established staggered launch dates or authorized-generic arrangements.

The competitive landscape was shaped by a limited number of manufacturers capable of meeting both technical bioequivalence requirements and the distribution controls associated with lenalidomide. Entry economics depended on launch timing, the number of approved competitors, the availability of multiple strengths, and any contractual limitations.

What was the revenue exposure from generic lenalidomide?

Revlimid was one of Celgene’s largest products before Bristol Myers Squibb acquired Celgene in 2019. The product generated multibillion-dollar annual revenue and represented a material portion of Celgene’s and later Bristol Myers Squibb’s oncology portfolio. [5]

Generic entry created several forms of exposure:

• Price erosion across approved strengths.
• Share loss to multiple ANDA holders.
• Reduced treatment revenue in multiple myeloma and myelodysplastic syndromes.
• Pressure on international and U.S. net sales.
• Lower value for remaining method-of-use and formulation rights.
• Increased rebate and contracting pressure.

The first generic entrant could obtain a meaningful commercial advantage, while subsequent entrants would accelerate price erosion. Settlement-controlled launches could moderate the rate of erosion by limiting the number of competitors or delaying broad competition.

How does Hikma’s case compare with a conventional generic patent dispute?

The case differed from a routine tablet or capsule ANDA dispute in three respects.

First, Revlimid had a high-value oncology franchise with multiple patented indications. Second, distribution and safety controls created regulatory and operational barriers beyond patent law. Third, the settlement value was tied to launch sequencing and market access, not only to whether a court would uphold a single patent.

The dispute also differs from biologic competition. Hikma’s product was a small-molecule generic, not a biosimilar. FDA approval depended on ANDA requirements for pharmaceutical equivalence and bioequivalence rather than the Public Health Service Act’s biosimilar framework.

Key Takeaways

• Celgene sued Hikma in the District of New Jersey over Hikma’s Paragraph IV ANDA for generic lenalidomide capsules.
• The case was part of Celgene’s broader effort to protect Revlimid through compound, formulation, method-of-use, dosing, and distribution-related rights.
• The action ended through settlement-related dismissal, not a reported trial judgment.
• The docket therefore does not establish whether the asserted patents were valid, infringed, or enforceable.
• Hikma later obtained FDA approval and entered the U.S. generic lenalidomide market under a controlled launch framework.
• Biosimilar analysis is not applicable because lenalidomide is a small-molecule drug.
• The commercial risk to Revlimid was substantial because the product generated multibillion-dollar revenue before generic competition.
• The principal remaining barriers were settlement terms, patent-specific expiration dates, FDA approval, distribution controls, and the number of competing generic suppliers.

FAQs

Did Hikma win the Celgene Revlimid patent case?

No reported merits judgment shows that Hikma won. The case ended through a negotiated disposition, so the public record does not resolve the asserted patent claims.

Was Hikma’s lenalidomide product an authorized generic?

Hikma’s U.S. market access was governed by settlement and commercial arrangements associated with generic lenalidomide. The precise contractual characterization of each product and launch channel should be distinguished from an authorized generic formally marketed by or for the brand owner.

Could Hikma launch generic lenalidomide before every Revlimid patent expired?

Yes. A settlement license can permit launch before all listed patents expire. The authorized date depends on the agreement, the product strengths, the patents covered, and regulatory approval.

Why was the Revlimid REMS relevant to patent litigation?

The risk-management system affected product distribution and market entry. It did not replace patent protection, but it increased the operational complexity of launching an approved generic.

Does the Hikma case create precedent for other lenalidomide challengers?

No. Because the case did not produce a reported merits decision, it provides limited precedential value on patent validity, infringement, or claim construction. Its primary value is as evidence of settlement and market-entry strategy.

References

1. U.S. District Court for the District of New Jersey. (2018-2021). Celgene Corporation v. Hikma Pharmaceuticals International Limited, No. 2:18-cv-13477-SDW-LDW. PACER/CourtListener docket records. https://www.courtlistener.com/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. Hikma Pharmaceuticals PLC. (2022). Hikma launches generic lenalidomide capsules in the United States. https://www.hikma.com/

4. U.S. Food and Drug Administration. (2022). FDA modifies Risk Evaluation and Mitigation Strategy for lenalidomide and thalidomide. https://www.fda.gov/

5. Bristol Myers Squibb. (2020). 2020 annual report. https://www.bms.com/investors/annual-reports.html